疫苗佐劑市場規模、佔有率、趨勢分析報告：按類型、給藥、應用、地區、細分市場預測，2023-2030

Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type (Pathogen, Adjuvant Emulsion, Particulate), By Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, By Region, And Segment Forecasts, 2023 - 2030

出版日期: 2023年11月29日 | 出版商:

Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

疫苗佐劑市場成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球疫苗佐劑市場預計將達到 19 億美元。

預計 2023 年至 2030 年該市場將以 2.3% 的複合年成長率成長。創新疫苗抗原的免疫抗原性不足，逐漸提高了佐劑研究在疫苗研發中的重要性。此外，對現有和新出現疾病的持久免疫力的關注預計也將推動對疫苗佐劑的需求。

此外，子宮頸癌盛行率的上升預計將提振市場。根據 NCBI 統計，每年約有 15,000 名女性死於子宮頸癌。一些公司，例如葛蘭素史克的 AS04 佐劑（人類乳突病毒疫苗），正在開發能夠更長時間增強免疫反應的佐劑。

疫苗佐劑市場報告亮點

疫苗佐劑市場依類型分為佐劑乳液、病原體、微粒、組合藥物等。 2022 年，顆粒物細分市場佔據最大的市場佔有率。
2022年，感染疾病業務佔最大收益佔有率，達68.1%。這一巨大比例是由於瘧疾、流感、甲型肝炎、乙型肝炎和丙型肝炎等感染疾病的盛行率逐漸增加。
給藥部分分為口服、皮內、鼻內、肌肉內等。由於有較好的免疫特異性，2022年給藥領域的收益佔有率最大，達33.8%。
北美地區主導市場，2022 年收益佔有率最大，為 41.7%。北美市場的成長是由新療法研發投資的增加以及致命傳染病數量的增加所推動的。

區域展望
按地區分類的疫苗佐劑市場：要點
北美洲
- 2018-2030 年市場估計與預測
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 丹麥
- 瑞典
- 挪威
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 泰國
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東/非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第8章競爭形勢

主要市場參與企業的最新趨勢和影響分析
市場參與企業分類
- GSK
- Novartis/CSL
- Agenus
- Adjuvance
- Novavax
- SPI Pharma
- Invivogen
- Avanti Polar Lipids
- Brentagg

簡介目錄圖表

Product Code: GVR-1-68038-612-7

Vaccine Adjuvants Market Growth & Trends:

The global vaccine adjuvants market is expected to reach USD 1.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 2.3% from 2023 to 2030. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

Vaccine Adjuvants Market Report Highlights:

The vaccine adjuvants market is segmented based on type into an adjuvant emulsion, pathogen, particulate, combination, and others. The particulate segment held the largest market share in 2022.
The infectious diseases segment accounted for the largest revenue share of 68.1% in 2022. This large share can be attributed to the gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others.
The administration segment is categorized into oral, intradermal, intranasal, intramuscular, and others. Due to better immune specificity, the intramuscular segment accounted for the largest revenue share of 33.8% in 2022
North America dominated the market and accounted for the largest revenue share of 41.7% in 2022. The factors contributing to the growth of the market in the North American region are a rise in investments for R&D of new therapeutics and an increase in fatal epidemic diseases.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Application
- 1.1.3. Administration type
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Application outlook
- 2.2.3. Administration outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Vaccine Adjuvants Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
3.4. Vaccine Adjuvants Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
  - 3.4.1.1. Supplier power
  - 3.4.1.2. Buyer power
  - 3.4.1.3. Substitution threat
  - 3.4.1.4. Threat of new entrant
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Technological landscape
  - 3.4.2.3. Economic Landscape

Chapter 4. Vaccine Adjuvants: Type Estimates & Trend Analysis

4.1. Vaccine Adjuvants Market: Key Takeaways
4.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Pathogen
- 4.3.1. Pathogen market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Adjuvant emulsion
- 4.4.1. Adjuvant emulsion market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Particulate
- 4.5.1. Particulate market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Combination
- 4.6.1. Combination market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Others
- 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Vaccine Adjuvants: Application Estimates & Trend Analysis

5.1. Vaccine Adjuvants Market: Key Takeaways
5.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Infectious diseases
- 5.3.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Cancer
- 5.4.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Others
- 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Vaccine Adjuvants: Administration Estimates & Trend Analysis

6.1. Vaccine Adjuvants Market: Key Takeaways
6.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Oral
- 6.3.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Intradermal
- 6.4.1. Intradermal market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Intranasal
- 6.5.1. Intranasal market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Intramuscular
- 6.6.1. Intramuscular market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Others
- 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Vaccine Adjuvants Market: Regional Estimates & Trend Analysis

7.1. Regional Outlook
7.2. Vaccine Adjuvants Market by Region: Key Takeaways
7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
  - 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Denmark
  - 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Norway
  - 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
  - 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
  - 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
  - 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
  - 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
  - 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
  - 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
- 8.2.1. GSK
  - 8.2.1.1. Company overview
  - 8.2.1.2. Financial performance
  - 8.2.1.3. Product benchmarking
  - 8.2.1.4. Strategic initiatives
- 8.2.2. Novartis/CSL
  - 8.2.2.1. Company overview
  - 8.2.2.2. Financial performance
  - 8.2.2.3. Product benchmarking
  - 8.2.2.4. Strategic initiatives
- 8.2.3. Agenus
  - 8.2.3.1. Company overview
  - 8.2.3.2. Financial performance
  - 8.2.3.3. Product benchmarking
  - 8.2.3.4. Strategic initiatives
- 8.2.4. Adjuvance
  - 8.2.4.1. Company overview
  - 8.2.4.2. Financial performance
  - 8.2.4.3. Product benchmarking
  - 8.2.4.4. Strategic initiatives
- 8.2.5. Novavax
  - 8.2.5.1. Company overview
  - 8.2.5.2. Financial performance
  - 8.2.5.3. Product benchmarking
  - 8.2.5.4. Strategic initiatives
- 8.2.6. SPI Pharma
  - 8.2.6.1. Company overview
  - 8.2.6.2. Financial performance
  - 8.2.6.3. Product benchmarking
  - 8.2.6.4. Strategic initiatives
- 8.2.7. Invivogen
  - 8.2.7.1. Company overview
  - 8.2.7.2. Financial performance
  - 8.2.7.3. Product benchmarking
  - 8.2.7.4. Strategic initiatives
- 8.2.8. Avanti Polar Lipids
  - 8.2.8.1. Company overview
  - 8.2.8.2. Financial performance
  - 8.2.8.3. Product benchmarking
  - 8.2.8.4. Strategic initiatives
- 8.2.9. Brentagg
  - 8.2.9.1. Company overview
  - 8.2.9.2. Financial performance
  - 8.2.9.3. Product benchmarking
  - 8.2.9.4. Strategic initiatives

簡介目錄圖表

List of Tables

Table 1 List of Abbreviations
Table 2 North America Vaccine Adjuvants market, by type, 2018 - 2030 (USD Million)
Table 3 North America vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 4 North America vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 5 North America vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 8 U.S. vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 9 Canada vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 10 Canada vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 11 Canada vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 12 Europe vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 13 Europe vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 14 Europe vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 15 Europe vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
Table 16 Germany vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 17 Germany vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 18 Germany vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 19 UK vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 20 UK vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 21 UK vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 22 France vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 23 France vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 24 France vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 25 Italy vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 26 Italy vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 27 Italy vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 28 Spain vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 29 Spain vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 30 Spain vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 31 Denmark vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 32 Denmark vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 33 Denmark vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 34 Sweden vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 35 Sweden vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 36 Sweden vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 37 Norway vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 38 Norway vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 39 Norway vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 40 Asia Pacific vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 41 Asia Pacific vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 42 Asia Pacific vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 43 Asia Pacific vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
Table 44 Japan vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 45 Japan vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 46 Japan vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 47 China vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 48 China vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 49 China vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 50 India vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 51 India vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 52 India vaccine adjuvants market, by administration, (USD Million) 2018 - 2030
Table 53 Australia vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 54 Australia vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 55 Australia vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 56 Thailand vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 57 Thailand vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 58 Thailand vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 59 South Korea vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 60 South Korea vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 61 South Korea vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 62 Latin America vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 63 Latin America vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 64 Latin America vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 65 Latin America vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
Table 66 Brazil vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 67 Brazil vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 68 Brazil vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 69 Mexico vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 70 Mexico vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 71 Mexico vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 72 Argentina vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 73 Argentina vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 74 Argentina vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa vaccine adjuvants market, by region, 2018 - 2030 (USD Million)
Table 79 South Africa vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 80 South Africa vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 81 South Africa vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 85 UAE vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 86 UAE vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 87 UAE vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)
Table 88 Kuwait vaccine adjuvants market, by type, 2018 - 2030 (USD Million)
Table 89 Kuwait vaccine adjuvants market, by application, 2018 - 2030 (USD Million)
Table 90 Kuwait vaccine adjuvants market, by administration, 2018 - 2030 (USD Million)